Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants
K. A. Parham, G. N. Kim, N. Saeedian, M. Ninkov, C. G. Richer, Y. Li, K. Wu, R. Rashu, S. D. Barr, E. J. Arts, S. M. M. Haeryfar, C. Y. Kang, R. M. Troyer
This study evaluates rVSV-based vaccines against SARS-CoV-2 variants, showing potent neutralizing antibodies and CD8+ T cell responses across multiple variants.
bioRxiv · Jul 19, 2022 · PreprintImmunology